Why prescribe more when you can get a similar effect with less?
YONSA is an innovative formulation of abiraterone acetate (AA) which provides1
No food restrictions1,2
YONSA is the only FDA-approved abiraterone acetate formulation that can be taken with or without food—which gives patients the flexibility to take it with no food restrictions.
More with less1,3
YONSA taken at a 500 mg dose with methylprednisolone provides similar bioavailability to 1000 mg of abiraterone acetate with corticosteroid. For this reason, YONSA may not be interchangeable with other abiraterone acetate products.
Therapeutic equivalence1,4*
The micronization of YONSA reduces the drug particle size down to 200-800 nanometers—10-200x smaller than conventional drug particles.1,4
This increases overall drug surface area, which improves dissolution and absorption.1 Thanks to the increased surface area and improved absorption, YONSA is the only FDA-approved abiraterone acetate to treat mCRPC at 500 mg.
*Compared to other formulations of abiraterone acetate
The most common adverse reactions (≥ 10%) are fatigue, joint swelling or discomfort, edema, hot flush, diarrhea, vomiting, cough, hypertension, dyspnea, urinary tract infection and contusion.
The most common laboratory abnormalities (> 20%) are anemia, elevated alkaline phosphatase, hypertriglyceridemia, lymphopenia, hypercholesterolemia, hyperglycemia, elevated AST, hypophosphatemia, elevated ALT and hypokalemia.
Prior Authorization (PA) Assistance
Sun Pharma is working to help your office navigate the PA process and remove obstacles to coverage. A peer-led video takes you through best practices and tips that could help expedite the electronic PA process and help your patients receive their YONSA therapy as prescribed, including:
- Understanding what you’ll need for the PA request
- Navigating questions, tiering, appeals and denials
- Tips to expedite appeals
Visit the YONSA team at Booth 1222 to see the Full House of Benefits for yourself, and to talk with a member of our team about viewing our peer-led video.
Visit www.yonsarx.com to learn more.
mCRPC= metastatic castration-resistant prostate cancer
INDICATION
YONSA (abiraterone acetate) in combination with methylprednisolone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC).
CONTRAINDICATIONS: None
IMPORTANT SAFETY INFORMATION
To avoid medication errors and overdose, be aware that YONSA tablets may have different dosing and food effects than other abiraterone acetate products.
Patients receiving YONSA should also receive a gonadotropin-releasing hormone (GnRH) analog concurrently or should have had bilateral orchiectomy.
WARNINGS AND PRECAUTIONS
Mineralocorticoid excess: Closely monitor patients with cardiovascular disease. Control hypertension and correct hypokalemia before treatment. Monitor blood pressure, serum potassium and symptoms of fluid retention at least monthly.
Adrenocortical insufficiency: Monitor for symptoms and signs of adrenocortical insufficiency. Adrenocortical insufficiency was reported in patients receiving abiraterone acetate in combination with corticosteroid, following an interruption of daily steroids and/or with concurrent infection or stress. Increased dosage of corticosteroids may be indicated before, during and after stressful situations.
Hepatotoxicity: Can be severe and fatal. Monitor liver function and modify, interrupt, or discontinue YONSA dosing as recommended. In post-marketing experience, there has been abiraterone acetate-associated severe hepatic toxicity, including reports of fulminant hepatitis, acute liver failure, and deaths.
Increased fractures and mortality in combination with radium Ra 223 dichloride: Use of YONSA plus methylprednisolone in combination with radium Ra 223 dichloride is not recommended.
Embryo-Fetal toxicity: YONSA can cause fetal harm and loss of pregnancy. Advise males with female partners of reproductive potential to use effective contraception during YONSA use and for 3 weeks after the final dose of YONSA. Females who are pregnant or may be pregnant should not handle YONSA tablets if broken, crushed, or damaged without protection, eg, gloves.
Hypoglycemia: Severe hypoglycemia has been reported in patients with pre-existing diabetes who are taking medications containing thiazolidinediones (including pioglitazone) or repaglinide. Monitor blood glucose in patients with diabetes and assess if antidiabetic agent dose modifications are required.
ADVERSE REACTIONS
The most common adverse reactions (≥10%) are fatigue, joint swelling or discomfort, edema, hot flush, diarrhea, vomiting, cough, hypertension, dyspnea, urinary tract infection, and contusion.
The most common laboratory abnormalities (>20%) are anemia, elevated alkaline phosphatase, hypertriglyceridemia, lymphopenia, hypercholesterolemia, hyperglycemia, elevated AST, hypophosphatemia, elevated ALT, and hypokalemia.
DRUG INTERACTIONS
Effect of other Drugs on YONSA
Strong CYP3A4 Inducers:
The co-administration of rifampin, a strong CYP3A4 inducer, decreased exposure of abiraterone by 55%. Avoid concomitant strong CYP3A4 inducers during YONSA treatment. If a strong CYP3A4 inducer must be co-administered, increase the YONSA dosing frequency.
Effects of YONSA on other Drugs
CYP2D6 Substrates:
Abiraterone is an inhibitor of the hepatic drug-metabolizing enzymes CYP2D6. Avoid co-administration of abiraterone acetate with substrates of CYP2D6 with a narrow therapeutic index. If alternative treatments cannot be used, consider a dose reduction of the concomitant CYP2D6 substrate drug in accordance with its Prescribing Information.
CYP2C8 Substrates:
Abiraterone is an inhibitor of the hepatic drug-metabolizing enzymes CYP2D6 and CYP2C8. Patients should be monitored closely for signs of toxicity related to a CYP2C8 substrate with a narrow therapeutic index if used concomitantly with abiraterone acetate.
To Report SUSPECTED ADVERSE REACTIONS, contact Sun Pharmaceutical Industries, Inc. at 1-800-818-4555 or FDA at 1-800-FDA-1088 or http://www.fda.gov/medwatch
Please see the Full Prescribing Information.
References:
1. Goldwater R., Hussaini A, Bosch B, Nemeth P. Comparison of a novel formulation of abiraterone acetate vs. the originator formulation in healthy male subjects: two randomized, open-label, crossover studies. Clin Pharmacokinet. 2017;56(7):803-813. 2. Hussaini A, Olszanski AJ, Stein CA, Bosch B, Nemeth P. Impact of an alternative steroid on the relative bioavailability and bioequivalence of a novel versus the originator formulation of abiraterone acetate. Cancer Chemo Pharmacol. 2017;80(3):479-486. 3. Zytiga® [prescribing information]. Horsham, PA: Janssen Biotech, Inc. 4. YONSA® [prescribing information]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.
YONSA is a registered trademark of Sun Pharmaceutical Industries Limited. All other trademarks are the property of their respective owners.
© 2025 Sun Pharmaceutical Industries, Inc. All rights reserved.
PM-US-YON-0853 03/2025